1 / 21

EXAMINE: CV End Points

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome. EXAMINE: CV End Points. SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications?.

zachery-guthrie
Download Presentation

EXAMINE: CV End Points

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

  2. EXAMINE: CV End Points

  3. SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications?

  4. SAVOR-TIMI 53: CV End Points

  5. Safety End Points

  6. Clinical Implications

  7. CV Events With Rosiglitazone

  8. Global Cost of Diabetes

  9. Insights From SAVOR-TIMI 53

  10. DPP-4 Inhibitors

  11. Hypoglycemia: Impact on Quality of Life

  12. Take-Home Messages

  13. Abbreviations

  14. Abbreviations (cont)

  15. References

  16. References (cont)

  17. References (cont)

More Related